Restasis (cyclosporine emulsion) is a topical formulation indicated for the treatment of reduced tear productoin due to inflammation from dry eye disease. While the routine, daily use of artificial tears provides symptomatic relief, Restasis helps fight the cause of the condition.
Approval of Restasis is based on four multicenter, randomized, clinical studies performed in approximately 1,200 patients with moderate to severe keratoconjunctivitis sicca.
Restasis demonstrated statistically significant increases in Schirmer wetting of 10 mm versus vehicle at six months in subjects whose tear production was presumed to be suppressed due to ocular inflammation. Data showed that 15% of subjects treated with Restasis showed increased tear production compared to 5% of vehicle treated patients. No increase in tear production was observed in subjects being treated with anti-inflammatory drugs or using punctal plugs.
Adverse events associated with the use of Restasis may include (but are not limited to) the following:
Restasis (cyclosporine ophthalmic emulsion) 0.05% contains a topical immunomodulator with anti-inflammatory effects. Cyclosporine, a fine white powder, is an immunosuppressive agent when administered systemically. Cyclosporine emulsion is thought to act as a partial immunomodulator. The exact mechanism of action is not known.
Evidence indicates that inflammation of both the lacrimal gland and ocular surface is at the root of keratoconjunctivitis sicca, commonly referred to as dry eye disease. Restasis helps to reduce that inflammation.
For additional information on Restasis or eye disease, please contact The Allergan web site
The Restasis (cyclosporine ophthalmic emulsion) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.